Mark Lebwohl
Impact in
- Dermatology top 0.01%
- Dermatology and Skin Diseases
- Immunology top 0.01%
- Psoriasis: Treatment and Pathogenesis
Papers in
- Immunology 576
- Psoriasis: Treatment and Pathogenesis 544
- Dermatology 318
- Dermatology and Skin Diseases 210
- Co-authors
- Alan Menter (48 shared papers)John Y. M. Koo (42 shared papers)Alice Bendix Gottlieb (79 shared papers)Richard G B Langley (42 shared papers)Abby S. Van Voorhees (27 shared papers)Kristian Reich (51 shared papers)Kim Alexander Papp (68 shared papers)Neil J. Korman (25 shared papers)
- Journals
- Journal of the American Academy of Dermatology (270 papers)British Journal of Dermatology (38 papers)Dermatology and Therapy (37 papers)Journal of the European Academy of Dermatology and Venereology (32 papers)Journal of Investigative Dermatology (28 papers)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Mark Lebwohl
928 papers receiving 45.0k citations
Mark Lebwohl's Hit Papers
Peers
Comparison fields: 5 of 173
- Dermatology 16.6k
- Immunology 27.7k
- Rheumatology 5.9k
- Immunology and Allergy 2.1k
- Pathology and Forensic Medicine 5.0k
Countries citing papers authored by Mark Lebwohl
This map shows the geographic impact of Mark Lebwohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lebwohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lebwohl more than expected).
Fields of papers citing papers by Mark Lebwohl
This network shows the impact of papers produced by Mark Lebwohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lebwohl. The network helps show where Mark Lebwohl may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Lebwohl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 992 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Hit paper breakdown → | 2014 | 1674 |
| 2 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Hit paper breakdown → | 2008 | 1182 |
| 3 | Guidelines of care for the management of psoriasis and psoriatic arthritis Hit paper breakdown → | 2008 | 1040 |
| 4 | The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Hit paper breakdown → | 2001 | 840 |
| 5 | Psoriasis Hit paper breakdown → | 2016 | 772 |
| 6 | Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Hit paper breakdown → | 2015 | 724 |
| 7 | Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis Hit paper breakdown → | 2015 | 709 |
| 8 | Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics Hit paper breakdown → | 2019 | 703 |
| 9 | Guidelines of care for the management of psoriasis and psoriatic arthritis Hit paper breakdown → | 2008 | 661 |
| 10 | 2007 | 655 | |
| 11 | Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials Hit paper breakdown → | 2018 | 535 |
| 12 | 1999 | 501 | |
| 13 | 2003 | 492 | |
| 14 | 2003 | 476 | |
| 15 | Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults Hit paper breakdown → | 2016 | 465 |
| 16 | 2009 | 464 | |
| 17 | 2014 | 449 | |
| 18 | 2011 | 395 | |
| 19 | 2009 | 389 | |
| 20 | 2012 | 386 |
About Mark Lebwohl
Mark Lebwohl is a scholar working on Immunology, Dermatology, Rheumatology, Pathology and Forensic Medicine and Epidemiology, having authored 992 papers that have together received 47.3k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (544 papers), Dermatology and Skin Diseases (210 papers), Autoimmune Bullous Skin Diseases (88 papers), Pharmaceutical studies and practices (57 papers), Health Systems, Economic Evaluations, Quality of Life (51 papers), Nonmelanoma Skin Cancer Studies (46 papers), Nail Diseases and Treatments (42 papers) and Asthma and respiratory diseases (39 papers). The work is most often cited by research in Dermatology (16.6k citations), Immunology (27.7k citations), Rheumatology (5.9k citations), Immunology and Allergy (2.1k citations) and Pathology and Forensic Medicine (5.0k citations). Mark Lebwohl has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Alan Menter, John Y. M. Koo, Alice Bendix Gottlieb, Richard G B Langley, Abby S. Van Voorhees, Kristian Reich, Kim Alexander Papp, Neil J. Korman, Kenneth B. Gordon and Steven R. Feldman. Their work appears in journals such as Journal of the American Academy of Dermatology, British Journal of Dermatology, Dermatology and Therapy, Journal of the European Academy of Dermatology and Venereology and Journal of Investigative Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.